首页> 外文期刊>Journal of Medicinal Chemistry >Mining Natural Products for Macrocycles to Drug Difficult Targets
【24h】

Mining Natural Products for Macrocycles to Drug Difficult Targets

机译:采矿天然产物用于宏杂种造成药物困难的目标

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Lead generation for difficult-to-drug targets that have large, featureless, and highly lipophilic or highly polar and/or flexible binding sites is highly challenging. Here, we describe how cores of macrocyclic natural products can serve as a high-quality in silico screening library that provides leads for difficult-to-drug targets. Two iterative rounds of docking of a carefully selected set of natural-product-derived cores led to the discovery of an uncharged macrocyclic inhibitor of the Keap1-Nrf2 protein- protein interaction, a particularly challenging target due to its highly polar binding site. The inhibitor displays cellular efficacy and is well-positioned for further optimization based on the structure of its complex with Keapl and synthetic access. We believe that our work will spur interest in using macrocyclic cores for in silico-based lead generation and also inspire the design of future macrocycle screening collections.
机译:对于具有大的、无特征的、高度亲脂性的或高度极性的和/或柔性结合位点的难制备药物靶点,铅的制备极具挑战性。在这里,我们描述了大环天然产物的核心如何作为一个高质量的电子筛选文库,为难以确定的药物靶点提供线索。对一组精心挑选的天然产物衍生核心进行了两轮迭代对接,发现了Keap1-Nrf2蛋白质-蛋白质相互作用的不带电荷的大环抑制剂,由于其高度极性结合位点,这是一个特别具有挑战性的靶点。该抑制剂显示出细胞功效,并且基于其与Keapl和合成通路的复合物的结构,可以进行进一步优化。我们相信,我们的工作将激发人们对使用大环芯进行硅基铅生产的兴趣,也将启发未来大环筛选系列的设计。

著录项

  • 来源
    《Journal of Medicinal Chemistry》 |2021年第2期|共19页
  • 作者单位

    Uppsala Univ Dept Chem BMC S-75123 Uppsala Sweden;

    Uppsala Univ Dept Chem BMC S-75123 Uppsala Sweden;

    AstraZeneca Dept Med Chem Res &

    Early Dev Early Cardiovasc Renal &

    Metab BioPharmaceut R&

    D S-43183 Molndal Sweden;

    AstraZeneca R&

    D Discovery Sci Discovery Biol S-43183 Molndal Sweden;

    AstraZeneca R&

    D Discovery Sci Struct Biophys &

    Fragment Based Lead Generat S-43183 Molndal Sweden;

    AstraZeneca R&

    D Discovery Sci Struct Biophys &

    Fragment Based Lead Generat S-43183 Molndal Sweden;

    Uppsala Univ Dept Chem BMC S-75123 Uppsala Sweden;

    AstraZeneca Dept Med Chem Res &

    Early Dev BioPharmaceut R&

    D Resp &

    Immunol S-43183 Molndal Sweden;

    AstraZeneca R&

    D Discovery Sci Struct Biophys &

    Fragment Based Lead Generat S-43183 Molndal Sweden;

    Drugs Neglected Dis Initiat DNDi CH-1202 Geneva Switzerland;

    AstraZeneca Dept Med Chem Res &

    Early Dev BioPharmaceut R&

    D Resp &

    Immunol S-43183 Molndal Sweden;

    Uppsala Univ Dept Chem BMC S-75123 Uppsala Sweden;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号